Ramírez L, Santos DM, Souza AP, Coelho EAF, Barral A, Alonso C, Escutia MR, Bonay P, de Oliveira CI, Soto M: Evaluation of immune responses and analysis of the effect of vaccination of the Leishmania major recombinant ribosomal proteins L3 or L5 in two different murine models of cutaneous. Vaccine 2013, 31:1312–1319.
(aqui)
Publicação LIP 2013
Four new antigenic proteins located in Leishmania ribosomes have been characterized: S4, S6, L3 and
L5. Recombinant versions of the four ribosomal proteins from Leishmania major were recognized by sera
from human and canine patients suffering different clinical forms of leishmaniasis. The prophylactic
properties of these proteins were first studied in the experimental model of cutaneous leishmaniasis
caused by L. major inoculation into BALB/c mice. The administration of two of them, LmL3 or LmL5
combined with CpG-oligodeoxynucleotides (CpG-ODN) was able to protect BALB/c mice against L. major
infection. Vaccinated mice showed smaller lesions and parasite burden compared to mice inoculated
with vaccine diluent or vaccine adjuvant. Protection was correlated with an antigen-specific increased
production of IFN- paralleled by a decrease of the antigen-specific IL-10 mediated response in protected
mice relative to non-protected controls. Further, it was demonstrated that BALB/c mice vaccinated with
recombinant LmL3 or LmL5 plus CpG-ODN were also protected against the development of cutaneous
lesions following inoculation of L. braziliensis. Together, data presented here indicate that LmL3 or LmL5
ribosomal proteins combined with Th1 inducing adjuvants, may be relevant components of a vaccine
against cutaneous leishmaniasis caused by distinct species.
Nenhum comentário:
Postar um comentário